- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07943078
A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 Trial of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors
The purpose of this study is to find out how safe and well-tolerated JNJ-99220732 is and to find out the most suitable dose ([putative] recommended phase 2 dose [pRP2D] regimen[s]) of JNJ-99220732 (Part 1-Dose Escalation). Also, to find out how safe and well-tolerated JNJ-99220732 is at the pRP2D regimen(s) as determined in Part 1 (Part 2- Dose Expansion).
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Study Contact
- Phone Number: 844-434-4210
- Email: Participate-In-This-Study1@its.jnj.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Histological or cytological diagnosis of locally advanced, or metastatic solid tumor, received greater than or equal to (>=) 1 prior line of therapy for recurrent or metastatic disease; progressed or relapsed after or be intolerant to standard therapy approved for the specific tumor type. Participants who actively decline available standard of care therapies are eligible upon documentation of their refusal.
i. Participants with NSCLC must not have known actionable driver alteration for which a targeted therapy is available.
ii. Demonstrated radiographic progression on most recent tumor assessment imaging
- Participants entering the study must have >=1 measurable lesion as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 that has not been previously irradiated
- Body weight >=35 kilogram (kg) and body mass index (BMI) >=18 kilogram per square meter (kg/m^2)
- Eastern cooperative oncology group (ECOG) performance status of 0 or 1
- Must provide informed consent as described in protocol which includes compliance with the requirements and restrictions listed in the protocol and in the informed consent form (ICF)
Exclusion criteria:
- Active central nervous system (CNS) involvement with the exception of brain metastases that are clinically stable and asymptomatic for greater than (>)2 weeks off treatment and who are off or receiving low-dose corticosteroid treatment for at least 2 weeks prior to first dose of study treatment
- Any other malignancy diagnosis other than the disease under study within 2 years prior to the first dose of study treatment, except for squamous and basal cell carcinoma of the skin, non-muscle invasive bladder cancer, or any malignancy considered cured or has minimal risk of recurrence within 1 year of first dose of study treatment
- Had major surgery within 14 days prior to first dose of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to participate in the trial
- External beam radiation therapy to soft tissue lesions within 14 days prior to start of study treatment
- History of solid organ or allogeneic hematopoietic stem cell transplant (HSCT)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: JNJ-99220732 (Part 1 and Part 2)
Participants will receive escalating doses of JNJ-99220732 to identify the (putative) recommended phase 2 dose (pRP2D) regimen(s) in Part 1 (dose escalation) of the study. In Part 2 (dose expansion), participants will receive JNJ-99220732 at the pRP2D regimen(s) determined in Part 1 until lost to follow-up, withdrawal of consent, start of subsequent anticancer therapy, completion of the post treatment follow-up or the sponsor decides to stop the trial, whichever occurs first. |
JNJ-99220732 will be administered intravenously. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with Adverse Events (AE) by Severity
Time Frame: Up to 3 years 2 months
|
An AE is any untoward medical occurrence in a clinical trial participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An assessment of severity grade will be made by the investigator according to the National cancer institute common terminology criteria for Adverse Events (NCI-CTCAE version 6.0) using the standard grades as follows: Grade 1- Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2- Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL); Grade 3- Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4- Life-threatening consequences; urgent intervention indicated; Grade 5- Death related to adverse event. |
Up to 3 years 2 months
|
|
Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)
Time Frame: Up to 21 days
|
A DLT is defined as any adverse event that is not clearly due to the underlying disease or extraneous causes that occurs during the DLT period. It includes any toxicity resulting in permanent treatment discontinuation or a delay in dosing of greater than (>)14 days, any Grade 5 toxicity and any death not clearly due to underlying disease or non-study treatment-related cause, high-grade hematological and non-hematological toxicities. |
Up to 21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum Concentration Time Profile of JNJ-99220732
Time Frame: Up to 3 years 2 months
|
Serum concentrations of JNJ-99220732 over time will be reported. |
Up to 3 years 2 months
|
|
Maximum Observed Concentration (Cmax) of JNJ-99220732
Time Frame: Up to 3 years 2 months
|
Cmax of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Trough Concentration (Ctrough) of JNJ-99220732
Time Frame: Up to 3 years 2 months
|
Ctrough of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Time to Maximum Concentration (Tmax) of JNJ-99220732
Time Frame: Up to 3 years 2 months
|
Tmax of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Area Under the Concentration-Time Curve from Time Zero to Last Measured Time Point (AUC 0-tau) of JNJ-99220732
Time Frame: Up to 3 years 2 months
|
AUC0-tau of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Accumulation Ratio of JNJ-99220732
Time Frame: Up to 3 years 2 months
|
Accumulation ratio of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Number of Participants with Anti-Drug Antibodies Against JNJ-99220732
Time Frame: Up to 3 years 2 months
|
Number of participants with anti-drug antibodies against JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Objective Response Rate
Time Frame: Up to 3 years 2 months
|
Objective Response Rate (ORR) is defined as percentage of participants with best objective response of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) criteria. |
Up to 3 years 2 months
|
|
Disease Control Rate (DCR)
Time Frame: Up to 3 years 2 months
|
DCR is defined as the percentage of participants who achieve a confirmed best overall response of CR, PR, or stable disease (SD) based on RECIST version 1.1. |
Up to 3 years 2 months
|
|
Radiographic Progression-Free Survival (rPFS)
Time Frame: Up to 3 years 2 months
|
Radiographic PFS was defined as the time (in months) interval from first dose to the first date of radiographic progression or death. Radiographic progression included progression by bone scan, defined as at least 2 new lesions on bone scan and progression of soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI) (according to RECIST v.1.1 criteria). |
Up to 3 years 2 months
|
|
Duration of Response (DOR)
Time Frame: Up to 3 years 2 months
|
DOR is defined as time from date of first documented response (CR/PR) until date of first documented progressive disease (PD) or death, whichever occurs first (according to RECIST v.1.1 criteria). |
Up to 3 years 2 months
|
Collaborators and Investigators
Investigators
- Study Director: Janssen Research & Development LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 99220732STM1001
- 2026-527759-24-00 (Registry Identifier: EUCT number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.